TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.

Main|Search|PHGKB




Last Posted: Jul 19, 2018

---

• TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.  
  Wang Wen-Xian et al. Journal of thoracic disease 2018 May 10(5) 2991-2998
• Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.  
  et al. JAMA oncology 2018 Jul e182078
• Richard Smith: Is precision medicine a fantasy?  
  R Smith, BMJ, July 13, 2018
• A decade in psychiatric GWAS research.  
  Horwitz Tanya et al. Molecular psychiatry 2018 Jun
• Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine.  
  McLean Anna E B et al. Journal of clinical medicine 2018 Jun 7(7)
• Genomic underpinnings of lifespan allow prediction and reveal basis in modern risks  
  TR Timmers et al, BioRXIV, July 2018
• Osimertinib effective in EGFR T790M-positive lung cancer.  
  Mayor Susan et al. The Lancet. Oncology 2017 18(1) e9
• Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.  
  Abbosh Christopher et al. Nature reviews. Clinical oncology 2018 Jul
• Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.  
  Aredo Jacqueline V et al. Current treatment options in oncology 2018 Jun 19(8) 43
• Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.  
  Jing Changwen et al. Molecular medicine reports 2018 Jun

more